丑时行TEC新辅助化疗治疗乳腺癌的疗效观察

发布时间：2018-02-23 18:19

本文关键词： 乳腺癌时辰化疗腋窝淋巴结转移灶临床疗效　出处：《广州中医药大学》2015年硕士论文　论文类型：学位论文

【摘要】：目的：对比分析以子午流注理论指导下建立的丑时TEC新辅助化疗方案与常规TEC方案在局部晚期乳腺癌治疗中的疗效及不良反应,拟证实丑时行TEC化疗治疗乳腺癌的优越性,并证实子午流注理论指导乳腺癌化疗的科学性与可行性。方法：分析我院2013年3月至2014年12月乳腺科收治的53例确诊乳腺癌患者,依据术前化疗方案不同进行临床分组,TEC丑时化疗组(治疗组)21例和TEC日间常规化疗组(对照组)32例。行3周期的新辅助化疗后,比较两组原发肿瘤、腋窝淋巴结新辅助化疗的疗效变化及不良反应发生情况。结果：治疗组、对照组有效率(RR=CR+PR)、病理完全缓解率(pCR)、临床完全缓解率(cCR)、部分缓解率(PR)、维持稳定(SD)分别为76.2%、14.3%、19%、57.1%、23.8%与59.4%、6.25%、9.4%、50%、40.6%,两组有效率相比具有统计学意义(P0.05)。分层分析中,两组原发肿瘤有效率分别为66.7%、56.25%,差异没有统计学意义(P0.05)；治疗组腋窝淋巴结转移灶有效率优于对照组(66.7% vs 53.1%)(P0.05)；乳房原发肿瘤有效率与腋窝淋巴结转移灶有效率相当(62.7% vs 58.5%),无统计学差异(P0.05)。化疗过程中两组白细胞减少发生率相当(66.7% vs 68.9%),无统计学差异(P0.05),治疗组的恶心呕吐及周围神经异常发生率低于对照组,具有统计学差异(P0.05)。结论：本研究提示丑时行TEC新辅助化疗治疗局部晚期乳腺癌的疗效高于常规TEC化疗,并且毒副反应小,安全可靠,临床可以运用。
[Abstract]:Objective: to compare and analyze the curative effect and adverse reactions of TEC neo-adjuvant chemotherapy regimen and routine TEC regimen in the treatment of locally advanced breast cancer under the guidance of Meridian abortion theory, in order to prove the superiority of TEC chemotherapy in the treatment of breast cancer. Methods: 53 patients with breast cancer admitted from March 2013 to December 2014 in our hospital were analyzed. According to the different preoperative chemotherapy regimen, the patients were divided into two groups: the treatment group (21 cases) and the control group (32 cases). After 3 cycles of neoadjuvant chemotherapy, the primary tumors were compared between the two groups. Effect of neoadjuvant chemotherapy on axillary lymph nodes and adverse reactions. Results: treatment group, In the control group, the effective rates of RRN CR PRA, pathological complete remission rate, clinical complete remission rate and partial remission rate were 76.2%, 14.31% and 57.18%, respectively, compared with 59.4% 6.4505040.640.60.The effective rates of the two groups were significantly higher than that of the control group (P 0.05). In the stratified analysis, the effective rate of the two groups was significantly higher than that of the control group (P < 0.05). The effective rate of primary tumor in the two groups was 66.7% and 56.25, respectively. There was no significant difference between the two groups (P 0.05); the effective rate of axillary lymph node metastasis in the treatment group was better than that in the control group (66.7% vs 53.1%; the effective rate of primary breast tumor was 62.7% vs the effective rate of axillary lymph node metastasis was 62.7%). The incidence of leukopenia in the two groups was 66.7% vs 68.9%, and there was no statistical difference between the two groups (P 0.05). The incidence of nausea and vomiting and peripheral nerve abnormality in the treatment group was lower than that in the control group. Conclusion: this study suggests that TEC neoadjuvant chemotherapy is more effective than conventional TEC chemotherapy in the treatment of locally advanced breast cancer, and its toxicity is small, safe and reliable, and can be used clinically.
【学位授予单位】：广州中医药大学
【学位级别】：硕士
【学位授予年份】：2015
【分类号】：R737.9

【参考文献】